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Abstract
Background: The prevalence of type 2 diabetes is rising, and most of these patients also have hypertension,
substantially increasing the risk of cardiovascular morbidity and mortality. The majority of these patients do not
reach target blood pressure levels for a wide variety of reasons. When a literature review provided no clear focus
for action when patients are not at target, we initiated a study to identify characteristics of patients and providers
associated with achieving target BP levels in community-based practice.
Methods: We conducted a practice- based, cross-sectional observational and mailed survey study. The setting was
the practices of 27 family physicians and nurse practitioners in 3 eastern provinces in Canada. The participants
were all patients with type 2 diabetes who could understand English, were able to give consent, and would be
available for follow-up for more than one year. Data were collected from each patient’s medical record and from
each patient and physician/nurse practitioner by mailed survey. Our main outcome measures were overall blood
pressure at target (< 130/80), systolic blood pressure at target, and diastolic blood pressure at target. Analysis
included initial descriptive statistics, logistic regression models, and multivariate regression using hierarchical
nonlinear modeling (HNLM).
Results: Fifty-four percent were at target for both systolic and diastolic pressures. Sixty-two percent were at systolic
target, and 79% were at diastolic target. Patients who reported eating food low in salt had higher odds of
reaching target blood pressure. Similarly, patients reporting low adherence to their medication regimen had lower
odds of reaching target blood pressure.
Conclusions: When primary care health professionals are dealing with blood pressures above target in a patient
with type 2 diabetes, they should pay particular attention to two factors. They should inquire about dietary salt
intake, strongly emphasize the importance of reduction, and refer for detailed counseling if necessary. Similarly,
they should inquire about adherence to the medication regimen, and employ a variety of patient-oriented
strategies to improve adherence.
Background
The age-standardized prevalence of type 2 diabetes in
Canada rose by a relative 21% from 2003 to 2007 to
6.2% overall [1]. Most of these patients with diabetes
also have hypertension, a modifiable risk factor for heart
disease. In a baseline phase preceding this study, 78.7%
of type 2 diabetes patients in family practices in the
Maritime Provinces had been diagnosed with hyperten-
sion [2], using routine office sphygmomanometers. This
is higher than one other comparable Canadian study
(63%) [3], but similar to a second (75.8%) [4]. As comor-
bidities, hypertension and diabetes substantially increase
the risk of cardiovascular morbidity and mortality [5].
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most patients with type 2 diabetes do not reach target
blood pressures. In the earlier baseline phase, only
27.1% of patients were at target (< 130/80) [2], within
the range of 13 - 36% reported at target in other studies
in community settings [6-10].
A review of the literature revealed a wide array of
patient, physician, and health system factors contribut-
ing to the success or failure in reaching target BP goals.
Many, such as patient age [4,11-17] and sex
[4,11,13,16,18-20] and physician age [12] and sex [12,14]
are not modifiable. Health system factors such as access
to drug insurance plans have been cited by physicians as
a major facilitator of care of patients with diabetes [21],
but that too is not amenable to action on the part of
the individual physician. Among the most frequently
cited reasons for poor control of blood pressure in
hypertensive patients is a lack of adequate drug treat-
ment, with calls for a more aggressive approach [22,23].
Our baseline data had shown that patients were already
taking an average of 2.5 antihypertensive medications
[2], close to the 2.9 found necessary to reach a target of
less than 130/80 in an American study [18].
The literature review provided no clear guidance to
our team of eight community family physicians that had
collected the baseline phase data regarding where to
focus their attention when patients are not at target
blood pressures. With the support of university collea-
gues, they initiated a study to identify characteristics of
patients and providers associated with achieving target
BP levels in patients with type 2 diabetes in typical com-
munity-based practice. This paper will outline which
characteristics were found to be significant and provide
suggestions for increased attention in office practice.
Methods
This practice-based, cross-sectional study which
included both observational and mailed survey compo-
nents was conducted in family physician and nurse prac-
titioner practices in the Maritime Family Practice
Research Network in 3 eastern provinces in Canada.
The study was first approved by our institutional
Research Ethics Board (CD-2004-221); it was subse-
quently approved by six more Research Ethics Boards
with jurisdiction over participating practices. Data for
this phase of our study was collected between January
2008 and June 2010. All participants signed informed
consent forms.
Subjects
Potential participants included all patients of each prac-
tice with diagnoses of type 2 diabetes and hypertension
who could understand English, were able to give con-
sent, and were expected to be available for follow-up for
more than one year. Patients were included if they had
their most recent BP measurement taken with a
BpTRU™ within the past six months in order to relate
that pressure with the results of the patient survey.
Because antihypertensive drug prescribing was one of
our study variables, only patients taking those medica-
tions were included in the analysis.
Data sources and measures
Data was obtained from three sources: the patient’s
medical record, a self-administered survey mailed to
each patient and a survey completed by each participat-
ing provider. Measures (potential predictor and outcome
variables) from all sources were guided by a modifica-
tion of the Andersen conceptual model of health service
utilization [24] and included a variety of individual
patient (population) characteristics and contextual sys-
tem and provider factors (Table 1).
Clinical data relevant to the diagnosis and manage-
ment of type 2 diabetes and hypertension were extracted
from each patient’s medical record. Individual level
patient characteristics included predisposing characteris-
tics (age, gender) and factors associated with the identi-
fication of evaluated need such as the durations of
diabetes and hypertension, targeted clinical factors
(HbA1C equal to or less than 7.0%, LDL-CHOL < 2.5
mmol/L, and Total CHOL:HDL-CHOL ratio < 4.0) [25],
renal status, and a co-morbidity index. Health service
use from the medical record was represented by the
intensity of antihypertensive drug prescribing. For each
patient, details pertaining to all prescribed antihyperten-
sive medications currently being taken at the time of BP
recording were extracted. Antihypertensive drug classes
included in the CHEP recommendations [26,27] were
then used in the calculation of prescribing drug “inten-
sity” through the adaptation of an approach first
described by Menard et al. [28]. Briefly, for each patient,
the total daily dose prescribed for each antihypertensive
medication was divided by the upper limit of the range
of doses usually effective for hypertension as listed in
the 2006 Compendium of Pharmaceuticals and Special-
ties [29]. The sum of “intensity” scores for each drug
was then calculated.
The main outcomes of interest, or evaluated health
status, were overall BP at target, systolic blood pressure
(SBP) at target and diastolic blood pressure (DBP) at
target. BP readings extracted from the patient medical
record were the most recent measures taken with an
automated oscillometric machine (BpTRU™). The
BpTRU™ readings were done according to a protocol
provided with the machine, using the average of the sec-
ond through fifth readings. Blood pressure at target was
defined as less than 130/80 mmHg, consistent with the
CHEP recommendations [26,27]. Details of clinical data
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first phase of the study [2].
Information pertaining to patients not normally found
in the medical record was obtained directly from them
using a survey questionnaire developed for this study.
Survey administration was by mail and followed a modi-
fied Dillman’s method [30]. Each eligible patient was
mailed an initial package containing a personalized letter
of invitation, information about the study, the question-
naire and a post-paid return envelope. A follow-up
reminder was sent to all who had not responded within
five weeks after the initial invitation. Survey materials
sent to patients were mailed from their provider’s office.
The patient survey solicited information regarding addi-
tional patient characteristics (predisposing characteris-
tics, enabling resources, perceived need) and health
behaviours (use of health services, personal health prac-
tices) (Table 1). To aid in the capture of some of this
information, two validated, reliable scales were included:
the Morisky Medication Adherence Scale, a four-item
self-report adherence measure to evaluate medication
adherence in hypertensive patients [31], and a comor-
bidity assessment instrument developed by E. A. Bayliss
to estimate the number of comorbid conditions and
patient’s perceived disease burden from these conditions
(a “comorbidity index”) [32].
To account for clustering of patients within provider
practices across the three provinces, contextual informa-
tion pertaining to the practice and the system they oper-
ate within were collected through a survey mailed to
each participating provider using the same method as
that for the patient survey. Items in this provider survey
solicited responses regarding provider demographics and
practice information.
Analysis
Following initial descriptive statistics, bivariate regres-
sion models were used to evaluate the crude association
between each potential predictor variable and all out-
comes of interest. This was followed by multivariate
analysis where hierarchical nonlinear modeling (HNLM)
was utilized in order to account for the clustering of
patients associated with a provider. Predictors found to
be significant at p ≤ 0.2 in the bivariate analyses were
considered for inclusion in the hierarchical multivariate
modeling. For the hierarchical analyses, all predictors
were tested for random or fixed slopes and accounted
for in the regression equations as required.
A manual stepwise procedure was used for the addi-
tion of individual predictors to build the model. Indivi-
dual level patient predictors (Level 1) were tested first,
followed by contextual system and provider predictors
Table 1 Andersen’s Conceptual Model of Health Service Utilization adapted to investigate BP outcome
ENVIRONMENT ® POPULATION CHARACTERISTICS ® HEALTH BEHAVIOUR ® OUTCOMES
Health
care
system
Predisposing
characteristics
Enabling
Resources
Need Use of Health Services Evaluated health
status
Level 1
Individual
Patient
factors
Demographics
-Age
-Gender
-Ethnicity
Social Structure
-Education
-Marital status
Personal/family
-Private drug
insurance
Evaluated need
-Duration of
hypertension
-Duration of
diabetes
-Body mass
index
-HbA1c
-HDL
-LDL
-Renal Status
-Co-morbidity
Perceived need
-Bayliss’ Comorbidity
Index
Antihypertensive drug
intensity
Health care system
-Diabetes
Education
Attendance
Personal health practices
-Medication
Adherence
(Morisky score)
-Blood Pressure
Self-Monitoring
-Smoking
-Physical activity
-Diet
-Alcohol
Consumption
Measured blood
pressure (BP)
-Overall BP at target
-Systolic BP at target
-Diastolic BP at target
Level 2
Contextual
Physician/
Practice/
factors
Province Provider
Characteristics
-Gender
-Years in Family
Medicine
-Payment type
-Practice type
-Practice nurse
(Y/N)
-Urban/Rural
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cant in the final model with a p-value ≤ 0.05.
HLM version 6.03 [33] was used for HNLM analyses.
SAS version 9.1 [34] was used for all other analyses.
Results
In total, 656 patients met the inclusion criterion of this
study and were asked to complete the self-administered
survey. Of these eligible patients, 588 completed the
patient survey for a response rate of 89.6%. Eighteen
respondents were removed from analyses due to missing
critical information, such as incomplete survey informa-
tion from their provider or antihypertensive medications
not being prescribed. This resulted in a final cohort of
570 for analysis. These 570 patients had been recruited
by 27 providers who represented a diverse group of
family physicians (n = 25) and nurse practitioners (n =
2) from urban and rural settings, and various practice
types and payment methods (Table 2). Only 11 or 1.9%
of patients were associated with a nurse practitioner
practice. Most patients (67.2%) came from practices in
which virtually all eligible patients had been approached
for participation. There were no statistically significant
differences between patients in all practices for age, gen-
der, blood pressure at target or antihypertensive drug
intensity score.
Individual patient characteristics are summarized in
Table 3. Overall 54.4% were at target for overall BP
(both SBP and DBP), 62.1% were at SBP target, and
79.3% were at DBP target.
Table 4 summarizes the results of the final multivariate
analysis and shows a variety of statistically significant pre-
dictors of reaching target pressures. No predisposing or
personal/family patient characteristics were significantly
associated with attaining overall target BP. Two evaluated
need characteristics (duration of diagnosis of hypertension,
renal status) and three personal health practices (salt
intake, medication adherence, BP self-monitoring) were
significantly associated. Compared to patients diagnosed
with hypertension over the past five years, those with a
five to ten year duration of diagnosis of hypertension had
greater chance of reaching overall targeted BP (adjusted
odd ratio [AOR] = 1.62; 95% confidence interval [CI] =
1.07-2.44). Lower odds of reaching target BP was asso-
ciated with patients diagnosed with overt nephropathy
compared to those with a normal renal status (AOR =
Table 2 Contextual System and Provider Characteristics (n = 27)
CATEGORICAL VARIABLES Physician Frequency (%) Overall Number of Patients (%)
System Characteristics
PROVINCE
New Brunswick 10 (37.04) 191 (33.51)
Nova Scotia 16 (59.26) 348 (61.05)
Prince Edward Island 1 (3.70) 31 (5.44)
Provider Characteristics
GENDER
Male 13 (48.15) 415 (72.81)
Female 14 (51.85) 155 (27.19)
MEAN YEARS IN PRACTICE (SD) 20.37 (10.52) —————————————
PROVIDER TYPE
Family Physician 25 (92.59) 559 (98.07)
Nurse Practitioner 2 (7.41) 11 (1.93)
PRACTICE SETTING
Urban 16 (59.26) 303 (53.16)
Rural 11 (40.74) 267 (46.84)
PAYMENT TYPE
Fee for Service 12 (44.44) 415 (72.81)
Other 15 (55.56) 155 (27.19)
PRACTICE TYPE
Private office/clinic (excluding free standing walk-in clinic) 12 (44.44) 464 (81.40)
Community Clinic, Health Centre or Hospital 8 (29.63) 89 (15.61)
Academic Health Sciences Centre 7 (25.93) 17 (2.98)
PRACTICE NURSE
No 8 (29.63) 280 (49.12)
Yes 19 (70.37) 290 (50.88)
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PREDISPOSING CHARACTERISTICS
Demographics Frequency (%) Number at BP Target (%)
AGE
< 55 years 82 (14.39) 38 (46.34)
55-64 years 178 (31.23) 107 (60.11)
65-74 years 187 (32.81) 102 (54.55)
75 + years 123 (21.58) 63 (51.22)
GENDER
Male 295 (51.75) 163 (55.25)
Female 275 (48.25) 147 (53.45
ETHNICITY
White 488 (85.61) 265 (54.30)
Other 14 (2.46) 9 (64.29)
Unknown 68 (11.93) 36 (52.94)
Social Structure
EDUCATION
Grade 8-11 261 (45.79) 145 (55.56)
Completed High School 100 (17.54) 49 (49.00)
More Education than High School 187 (32.81) 101 (54.01)
Unknown Education 22 (3.86) 15 (68.18)
MARITAL STATUS
Married/Common Law 385 (67.54) 211 (54.81)
Single/Separated/Widowed/Divorced 185 (32.46) 99 (53.51)
ENABLING RESOURCES
Personal/Family
PATIENT INSURANCE
No 63 (11.21) 36 (57.14)
Yes 499 (88.79) 268 (53.71)
NEED
Evaluated Need (Clinical) Frequency (%)
YEARS SINCE HYPERTENSION DIAGNOSIS
In the past 5 years 126 (22.11) 64 (50.79)
5 to 10 years 163 (28.60) 102 (62.58)
Over 10 years 277 (48.60) 142 (51.26)
I do not remember 4 (0.70) 2 (50.00)
YEARS SINCE DIABETES DIAGNOSIS
In the past 5 years 164 (28.77) 86 (52.44)
5 to 10 years 161 (28.25) 98 (60.87)
Over 10 years 237 (41.58) 122 (51.48)
I do not remember 8 (1.40) 4 (50.00)
GLYCEMIC CONTROL
Controlled (HbA1c ≤ 7) 316 (56.13) 177 (56.01)
Uncontrolled (HbA1c > 7) 247 (43.87) 127 (51.42)
LIPIDS: LDL-CHOL
Controlled (LDLc < 2.5) 408 (72.47) 229 (56.13)
Uncontrolled (LDLc ≥ 2.5) 155 (27.53) 78 (50.32)
LIPIDS: HDL-CHOL
Controlled (Ratio TG:HDL < 4) 373 (65.67) 208 (55.76)
Uncontrolled (Ratio TG:HDL ≥ 4) 195 (34.33) 101 (51.79)
RENAL STATUS
Missing 64 (11.23) 24 (37.50)
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Normal 335 (58.77) 198 (59.10)
Microalbuminuria 83 (14.56) 51 (61.45)
Overt Nephropathy 88 (15.44) 37 (42.05)
Perceived Need (Self-Report) Frequency (%)
BAYLISS MEAN DISEASE COUNT (SD) 7.88 (4.56)
USE OF HEALTH SERVICES
MEAN INTENSITY OF ANTIHYPERTENSIVE MEDICTIONS (SD) 1.84 (1.01)
Health Care System
DIABETES EDUCATION CLINIC ATTENDANCE (PAST YEAR)
Zero Visits 386 (67.72) 205 (53.11)
One visit 95 (16.67) 55 (57.89)
Two or More Visits 89 (15.61) 50 (56.18)
Personal Health Practices
MEDICATION ADHERENCE
High Adherence 404 (70.88) 221 (54.70)
Medium Adherence 110 (19.30) 55 (50.00)
Low Adherence 9 (1.58) 3 (33.33)
Missing 47 (8.25) 31 (65.96)
BLOOD PRESSURE SELF-MONITORING
No 224 (39.30) 131 (58.48)
Sometimes 241 (42.28) 134 (55.60)
Often 105 (18.42) 45 (42.86)
SMOKING
Current 62 (10.88) 35 (56.45)
Past 253 (44.39) 144 (56.92)
Never 225 (39.47) 119 (52.89)
Unknown 30 (5.26) 12 (40.00)
PHYSICAL ACTIVITY
Not able to do physical activity 106 (18.86) 61 (57.55)
Once a week or less 143 (25.44) 74 (51.75)
2-3 times per week 157 (27.94) 89 (56.69)
4 or more times per week 156 (27.76) 82 (52.56)
EATING FOODS LOW IN SALT
No 138 (24.34) 63 (45.65)
Yes 429 (75.66) 244 (56.88)
ALCOHOL
Non or Occasional Drinker 392 (68.77) 210 (53.57)
Mild Drinker 164 (28.77) 92 (56.10)
Heavy Drinker 14 (2.46) 8 (57.14)
EVALUATED HEALTH STATUS Frequency (%)
OVERALL BLOOD PRESSURE AT TARGET
No 260 (45.61)
Yes 310 (54.39)
SYSTOLIC BLOOD PRESSURE AT TARGET
No 216 (37.89)
Yes 354 (62.11)
MEAN SYSTOLIC BLOOD PRESSURE (SD) 126.06 (15.51)
DIASTOLIC BLOOD PRESSURE AT TARGET
No 118 (20.70)
Yes 452 (79.30)
MEAN DIASTOLIC BLOOD PRESSURE (SD) 70.96 (9.94)
NOTE: Sum of participants for each variable may not add to n = 570 due to missing responses.
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OR (95% CL)
VARIABLE BP at Target
(< 130/80 mmHg)
Systolic BP at Target
(< 130 mmHg)
Diastolic BP at Target
(< 80 mmHg)
INDIVIDUAL LEVEL-1 PATIENT FACTORS
Predisposing characteristics
AGE
< 55 years ————————————— —————————————
55-64 years 0.93 (0.54-1.60) 1.87 (0.88-3.89)
65-74 years 0.62 (0.32-1.18) 3.56 (1.67-7.56)*
75 + years 0.48 (0.25-0.96)* 6.12 (2.66-14.12)*
GENDER
Male —————————————
Female 2.09 (1.03-4.25)*
Evaluated Need
YEARS SINCE HYPERTENSION DIAGNOSIS
In the past 5 years —————————————
5 to 10 years ago 1.62 (1.07-2.44)*
Over 10 years ago 1.04 (0.67-1.60)
I do not remember 1.12 (0.25-4.96)
LIPIDS: LDL-CHOL
Uncontrolled —————————————
Controlled 1.68 (1.14-2.49)*
RENAL STATUS
Missing 0.52 (0.28-1.01) 0.45 (0.23-0.87)*
Normal ————————————— —————————————
Microalbuminuria 1.10 (0.70-1.72) 1.28 (0.79-2.07)
Overt Nephropathy 0.48 (0.33-0.69)* 0.48 (0.31-0.76)*
Personal Health Practices
MEDICATION ADHERENCE
High Adherence ————————————— —————————————
Medium Adherence 0.72 (0.50-1.04) 0.80 (0.54-1.19)
Low Adherence 0.29 (0.09-0.86)* 0.34 (0.12-0.96)*
Missing 1.65 (0.79-3.43) 1.87 (0.92-3.82)
BLOOD PRESSURE SELF-MONITORING
No ————————————— —————————————
Sometimes 0.87 (0.58-1.30) 0.79 (0.53-1.18)
Often 0.51 (0.33-0.79)* 0.47 (0.28-0.80)*
EAT FOODS LOW IN SALT
No ————————————— —————————————
Yes 1.74 (1.25-2.41)* 2.35 (1.49-3.70)*
NO CONTEXTUAL PHYSICIAN OR SYSTEM LEVEL-2 FACTORS WERE SIGNIFICANT IN THE HLM MODEL
OR (95% CL)
VARIABLE BP at Target
(< 130/80 mmHg)
Systolic BP at Target
(< 130 mmHg)
Diastolic BP at Target
(< 80 mmHg)
INDIVIDUAL LEVEL-1 PATIENT FACTORS
Predisposing characteristics
AGE
< 55 years ————————————— —————————————
55-64 years 0.93 (0.54-1.60) 1.87 (0.88-3.89)
65-74 years 0.62 (0.32-1.18) 3.56 (1.67-7.56)*
75 + years 0.48 (0.25-0.96)* 6.12 (2.66-14.12)*
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ciated with greater odds of reaching target BP (AOR =
1.74; 95% CI = 1.25-2.41). Low adherence to medication
regimen (versus high) as reported on the Morisky Medica-
tion Adherence Scale was associated with lower odds of
reaching target BP (AOR = 0.29; 95% CI = 0.09-0.86) as
was the patient self-monitoring their BP (often versus no,
AOR = 0.51; 95% 0.33-0.79).
Factors significantly associated with reaching SBP tar-
get included a predisposing characteristic (age), an eval-
uated need factor (renal status) and personal health
practices (medication adherence and BP self-monitor-
ing). All were associated with lower odds of attaining
SBP target. Age greater than 75 years was associated
with lower odds for reaching target as were patients
diagnosed with overt nephropathy, with low medication
adherence and often self-monitoring their BP.
The attainment of DBP target was significantly asso-
ciated with age and gender (predisposing characteris-
tics), controlled low-density lipoprotein cholesterol
(LDL-CHOL) (an evaluated need) and salt intake (a per-
sonal health practice). Female patients had twice the
odds of being at DBP target as males (AOR = 2.09; 95%
CI = 1.03-4.25) while patients 65 years of age and older
were more than three times as likely as patients < 55
years. Also associated with greater odds of attaining
DBP target were patients with controlled LDL-CHOL
(AOR = 1.68; 95% CI = 1.14-2.49) and those reporting
eating foods low in salt (AOR 2.35; 95% CI 1.49-3.70).
Contextual factors pertaining to the system or provi-
ders (level 2) did not add significantly to the final multi-
variate models. However there was significant variability
in BP at target across providers, which justified the use
of the multi-level method.
Table 4 Statistically Significant Predictors for Reaching Target Blood Pressure (Continued)
GENDER
Male —————————————
Female 2.09 (1.03-4.25)*
Evaluated Need
YEARS SINCE HYPERTENSION DIAGNOSIS
In the past 5 years —————————————
5 to 10 years ago 1.62 (1.07-2.44)*
Over 10 years ago 1.04 (0.67-1.60)
I do not remember 1.12 (0.25-4.96)
LIPIDS: LDL-CHOL
Uncontrolled —————————————
Controlled 1.68 (1.14-2.49)*
RENAL STATUS
Missing 0.52 (0.28-1.01) 0.45 (0.23-0.87)*
Normal ————————————— —————————————
Microalbuminuria 1.10 (0.70-1.72) 1.28 (0.79-2.07)
Overt Nephropathy 0.48 (0.33-0.69)* 0.48 (0.31-0.76)*
Personal Health Practices
MEDICATION ADHERENCE
High Adherence ————————————— —————————————
Medium Adherence 0.72 (0.50-1.04) 0.80 (0.54-1.19)
Low Adherence 0.29 (0.09-0.86)* 0.34 (0.12-0.96)*
Missing 1.65 (0.79-3.43) 1.87 (0.92-3.82)
BLOOD PRESSURE SELF-MONITORING
No ————————————— —————————————
Sometimes 0.87 (0.58-1.30) 0.79 (0.53-1.18)
Often 0.51 (0.33-0.79)* 0.47 (0.28-0.80)*
EAT FOODS LOW IN SALT
No ————————————— —————————————
Yes 1.74 (1.25-2.41)* 2.35 (1.49-3.70)*
NO CONTEXTUAL PHYSICIAN OR SYSTEM LEVEL-2 FACTORS WERE SIGNIFICANT IN THE HLM MODEL
NOTE: Only variables found to be statistically significant in the final hierarchical models are included.
* Statistically significant
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Of the 570 patients included in this analysis, 54.4% had
achieved both SBP and DBP targets (< 130/80), much
higher than the 27.1% reported in the baseline phase
and comparable to a large study in Ontario, Canada,
which also used BpTRU™ measurements (50.3%) [7].
Two potential explanations for this might be 1) more
appropriate treatment consistent with CHEP recommen-
dations [35,36], and 2) the use of automated BP
machine which reduces white coat effect [37,38].
The remainder of the discussion will focus on three
significant factors found by our study that potentially
can be modified by interventions of health practitioners
caring for hypertension. Patients who reported low med-
ication adherence and self-monitoring of blood pressure
were less likely to have achieved overall BP target levels
while patients eating foods low in salt were more likely.
These factors can be influenced by a wide array of
health care providers.
Our results are in keeping with other studies that
report an association between medication adherence and
blood pressure control. In a study by Casson et al., poor
adherence was associated with increases in systolic blood
pressure when patients were monitored over an 18
month period [39]. Morris et al. reported that non adher-
ent patients had higher systolic and diastolic blood pres-
sures compared to adherent patients [40], and a meta-
analysis of six studies by DiMatteo et al. showed that
patients adherent to hypertensive medication had three
times the odds of having better overall blood pressure
control than patients who were non-adherent [41]. In the
original study validating the Morisky Medication Adher-
ence Scale, 75% of patients who reported high adherence
had their BP under adequate control compared to 47% of
patients who reported low adherence [31].
A review of strategies to enhance hypertensive medi-
cation adherence found that no single intervention has
emerged as superior to others. It is recommended that a
patient-centered approach that is tailored to overcome
specific patient barriers may be the best strategy to
improve adherence to hypertensive medication [42]. A
variety of steps can be taken in primary care that have
been shown to be effective in improving adherence:
decreasing the number of daily doses [43], giving written
directions and ensuring that patients understand the
treatment regimen [44], home [45], or self [46] monitor-
ing, and using medications with fewer side effects [47].
It has also been shown that pharmacist intervention can
reduce SBP [48], and a recent study has reported that
family physicians believe that more communication with
pharmacists on the adherence issue could improve it
[49]. A helpful table of strategies has been posted on the
web by CHEP http://hypertension.ca/chep/therapy-
tables/#table 5. Further research could clarify which of
these strategies is most effective in improving adherence
and lowering blood pressure.
The association of self-monitoring of blood pressure
with a lower likelihood of achieving BP targets contrasts
with much of the literature on the topic. Bray et al.
reported on a review of 25 randomized controlled trials
that had been published by 2009 that included self-mon-
itoring and self-management of blood pressure as an
intervention [50]. Twelve of those studies had a co-
intervention with the self-monitoring; examples include
patient education, contact with a health professional
such as a nurse or pharmacist, phone contact, home
visit, or telemetry. They concluded that self-monitoring
“reduces blood pressure by a small but significant
amount” [50]. Subsequently, McManus et al. demon-
strated that telemonitoring and self-management (self-
monitoring plus self-titration of antihypertensive medi-
cations) were effective in controlling systolic BP [51].
Bosworth et al. conducted a randomized trial that
included self-monitoring as one arm of the study. They
f o u n dt h a ts e l f - m o n i t o r i n gcombined with a tailored
behavioral telephone intervention “improved BP control,
systolic BP, and diastolic BP at 24 months relative to
usual care” but the differences with self-monitoring
alone were not significant [52].
Our study was an observational study, with no explicit
intervention for self-monitoring. The data presented
came from the patient survey response to the question
“Do you check your blood pressure outside of your doc-
tor’s office?” Response options were “No,”“ Sometimes,”
or “Often.” Those who responded “often” were less
likely to be at target (overall and SBP). We have no evi-
dence to determine how many patients were advised to
self-monitor by their doctor or nurse practitioner as a
component of “usual care,” or how many chose to do it
themselves at home or in a setting such as a pharmacy.
There was no structured co-intervention. Our study
design did not provide us with evidence to explain the
apparent difference with previous literature. We have
speculated that individuals who were not at target might
be more likely to be concerned about their BP and
therefore check it between office visits. It may also be
that, without a co-intervention, self-monitoring alone
offers a small [50] to no [52] advantage.
Our finding that patients who report a low salt diet
are more likely to be at overall target and diastolic BPs
comes as no surprise and gives support to current
guidelines [27]. It strongly suggests where health care
providers could focus their attention when dealing with
patients whose pressures are still higher than desired.
Discussion of salt restriction, on an equal footing with
the medications they must take, will emphasize to the
patient the importance of this restriction. A verbal “pre-
scription” to specifically decrease salt can accompany
Putnam et al. BMC Family Practice 2011, 12:86
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Page 9 of 11written prescriptions for medications. A referral to, and
conversation with, a nutritionist or diabetes educator
regarding counseling on diet and sodium reduction,
could ensure that this is treated as a high priority by the
patient.
Our “real world” community practice setting, in rural
and urban locations with a variety of available resources
and supports for patients, is a strength of this study. A
small number of academic practices (10) contributed
only 8% of the patient cohort. None of the practices had
a special focus on diabetes; all were broad primary care
practices of physicians and nurse practitioners interested
in contributing to research. As well, our high patient
survey response rate (89.6%) reinforces the value of our
data and enhances the generalizability of our findings.
An additional strength is the use of hierarchical non-
linear modeling which allowed us to control for the
clustering of patients within practices and the variance
between providers.
One of the limitations of our study is that the popula-
tion is less ethnically diverse than the general Canadian
population. Some measures were derived from a self-
r e p o r t e dm a i l e ds u r v e ya n dm a yb es u b j e c tt oo v e r -o r
under-reporting. However, commonly biased self-report
measures (such as age, weight, and smoking status) all
came from the provider, not the patient. Additionally,
8% of the data for medication adherence was missing.
Only patients with an available BpTRU™ measurement
were included in analysis and because of this, a small
number of patients could not be included. Their provi-
ders could not obtain a BpTRU™ reading due to the
size and shape of the arm. These were very high BMI
patients with a “conically” shaped arm.
Conclusions
Although numerous factors have been shown to be
associated with achieving BP targets, our study identified
two specific issues that health practitioners should focus
on when treating patients who are still not at target.
They should emphasize salt-restriction, possibly with
referral to a nutritionist, and employ patient-centered
strategies to assess and enhance medication adherence.
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